HBK Sorce Advisory LLC Makes New $4.07 Million Investment in Thermo Fisher Scientific Inc. $TMO

HBK Sorce Advisory LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 7,047 shares of the medical research company’s stock, valued at approximately $4,072,000.

Other hedge funds have also recently added to or reduced their stakes in the company. J. Stern & Co. LLP lifted its stake in Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares during the last quarter. Norges Bank acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $3,072,744,000. Bank of New York Mellon Corp bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $1,974,561,000. Auto Owners Insurance Co lifted its stake in shares of Thermo Fisher Scientific by 57,845.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after purchasing an additional 2,423,706 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. increased its position in Thermo Fisher Scientific by 2,183.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company’s stock worth $770,000,000 after buying an additional 1,270,643 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.3%

Shares of TMO opened at $586.62 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a 50-day moving average price of $531.72 and a two-hundred day moving average price of $508.48. The stock has a market cap of $216.90 billion, a price-to-earnings ratio of 31.56, a P/E/G ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company’s revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of analyst reports. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price objective for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Finally, Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 5,850 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at $8,574,720. The trade was a 28.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 4,608 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $586.12, for a total value of $2,700,840.96. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock worth $30,643,589 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.